×

Biotech and Pharmaceuticals Pharmaceuticals

  • Caterpillar rose 7.9 percent and McDonald's jumped 5.6 percent, while biotech drug maker Biogen rose 3.6 percent. Stocks are moving higher on Wall Street after Caterpillar, McDonald's and other big companies reported solid earnings. Caterpillar jumped 6.9 percent in midday trading Tuesday, while McDonald's rose 5 percent.

  • Bottles of Eli Lilly's Cymbalta on a pharmacy shelf in Princeton, Illinois.

    Eli Lilly reported a bigger-than-expected profit as the drugmaker benefited from higher demand for its newer products including diabetes treatment Trulicity.

  • *Shares rise 4.8 pct to $290.20 premarket. Shares of the company, which spun off its hemophilia business in February, were up 4.8 percent at $290.20 in pre-market trading on Tuesday. "We saw continued stability in our MS business, executed a strong launch of Spinraza, grew market share for our biosimilars business across Europe, and reinforced the intellectual...

  • TEL AVIV, April 25- Teva Pharmaceutical Industries hopes to resume some production at its newly purchased Mexican plant in the coming months, but an overhaul needed to bring the factory up to speed will take a few years, the company said on Tuesday. Rimsa's previous owners, the Espinosa family, deny this, and the two sides are locked in a legal battle.

  • LLY CEO: New products drove 'solid' growth

    David Ricks, Eli Lilly CEO, talks about the company's quarterly earnings, the Affordable Care Act, innovation in drug therapy and meeting with the FDA to talk about getting their new arthritis drug approved.

  • April 25- Biogen Inc reported a 3 percent rise in quarterly revenue, helped by higher-than-expected sales of its newly launched spinal muscular atrophy drug, Spinraza. However, net income attributable fell to $747.6 million, or $3.46 per share, in the first quarter ended March 31, from $970.9 million, or $4.43 per share, a year earlier. Total revenue rose to $2.81...

  • However, the Indianapolis- based drugmaker has suffered setbacks recently, with the U.S. Food and Drug Administration earlier this month declining to approve a new drug for rheumatoid arthritis made by Lilly and partner Incyte Corp. The drugmaker on Tuesday posted a net loss of $110.8 million, or 10 cents per share, in the first quarter, compared with a profit of...

  • The drugmaker said on Tuesday net loss was $110.8 million, or 10 cents per share, in the first quarter ended March 31, from $440.1 million, or 41 cents per share, a year earlier. Lilly recognized a charge of $857.6 million in the latest quarter related to the acquisition of CoLucid Pharmaceuticals. Revenue rose to $5.23 billion from $4.87 billion.

  • INDIANAPOLIS— Eli Lilly and Co. booked a $110.8 million loss in the first quarter, as the drugmaker absorbed a charge tied to its purchase of CoLucid Pharmaceuticals, but the insulin maker's bottom line beat expectations and it reaffirmed its 2017 forecast. Analysts expected, on average, earnings of 96 cents per share on $5.26 billion in revenue, according to...

  • *Agreed Akorn bid of $34 per share. FRANKFURT, April 25- German healthcare group Fresenius SE& Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars arm of Germany's Merck KGaA. But his successor, former finance chief Stephan Sturm, is lifting the pace, having already bought a Spanish hospital...

  • GENEVA— Swiss pharmaceuticals group Novartis says net income fell 15 percent in the first quarter, as it continued to adjust to generic competition for its Gleevec leukemia drug and stopped work on a hoped-for treatment for heart failure. The Basel- based company said net income dropped to $1.7 billion in the quarter, compared to $2.01 in the year-earlier...

  • Tim Wentworth, CEO of Express Scripts.

    The fact that Anthem wants to cut ties with Express Scripts is "perplexing," Express Scripts CEO Tim Wentworth told CNBC on Monday.

  • *Agreed Akorn bid of $34 per share. FRANKFURT, April 24- German healthcare conglomerate Fresenius SE& Co KGaA revved up the pace of its deals by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion, and in a separate agreement, the biosimilars unit of German peer Merck KGaA. A lot has been done in that area in the recent past, "Fresenius Chief Executive Stephan...

  • SAO PAULO, April 24- Johnson& Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA, two people with knowledge of the matter said on Monday. The owners of investment vehicles Igarapava Participações SA and Maiorem SA de CV, which hold a...

  • Upset NYSE Trader

    Check out which stocks posted moves after the bell on Monday.

  • FRANKFURT, April 24- Acquisitive German healthcare conglomerate Fresenius SE& Co KGaA revved up its deals pace by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion, and in a separate deal, the biosimilars unit of German peer Merck KGaA. In a transaction that has the backing of Akorn's management, Fresenius will pay $34 per share and take on Akorn's net...

  • Express Scripts

    Express Scripts CEO Tim Wentworth speaks to CNBC's Meg Tirrell about Q1 earnings and the company's contract with Anthem.

  • SAO PAULO, April 24- Johnson& Johnson, Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout, two people with knowledge of the matter said on Monday. Families owning investment vehicles Igarapava Participações SA and Maiorem SA de CV, which hold a combined 34 percent of...

  • The eventual market for the complex disease, formally known as Non-alcoholic Steatohepatitis, is forecast to be $20 billion to $35 billion as populations with fatty diets increasingly fall victim to a condition with no approved treatments. "We are actively looking on the outside for opportunities... to complement our internal program," Morris Birnbaum, chief...

  • The headquarters of German health care company Fresenius is seen at the company's headquarter in Bad Homburg near Frankfurt am Main, western Germany.

    German healthcare conglomerate Fresenius is close to acquiring generic drugmaker Akorn in an all-cash deal valuing the company at more than $4 billion